Visual Exploration and Attention: Studies in Patients With Schizophrenia and Autism Spectrum Disorders

Schizophrenia Clinical Trial

Official title:

Visual Exploration and Attention : Studies in Patients With Schizophrenia and Autism Spectrum Disorders

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00914030
• Other study ID #: 2008-A01459-46
• Status: Recruiting
• Phase: N/A
• First received: June 2, 2009
• Last updated: August 25, 2016
• Start date: June 2009
• Est. completion date: December 2016

Study information

• Verified date: August 2016
• Source: University Hospital, Strasbourg, France
• Contact: GIERSCH Anne, MD
• Email: giersch[@]unistra.fr
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Observational

Clinical Trial Summary

The aim of the protocol is to better understand the impairments in visual processing, as such impairments may induce social interaction difficulties in subjects with autism spectrum disorders (adults and children) and schizophrenia, like face exploration.The same protocol will be used for the three populations, each population being compared with matched controls. The explorations are designed to test two different hypotheses regarding the mechanisms of the visual perception difficulties of the two populations. Even though difficulties to extract the global form of objects have been described in both subjects with autism and schizophrenia, we will test two different hypotheses for the two populations. We will test the hypothesis that subjects with autism display an advantage for the processing of local information arising at an early level of processing, whereas disorders observed in patients with schizophrenia originate from attention disorders. The protocol includes three consecutive studies, each one being applied in each of the three populations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 140
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 7 Years to 55 Years

Eligibility

Inclusion Criteria:

• IQ above 70, as evaluated with the WAIS III in adults and with the WISC in children

• signed consent

• DSM IV criteria in case of autism spectrum disorders or schizophrenia

Exclusion Criteria:

• grave or non stabilized somatic pathology

• pathology affecting the central nervous system; other than the studied pathologies

• intake of psychotropic drug, except for patients

• invalidating sensory processes

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autism Spectrum Disorders
• Autistic Disorder
• Child Development Disorders, Pervasive
• Disease
• Schizophrenia

Intervention

Other:
• Neuropsychological evaluation
Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear

Locations

Country	Name	City	State
France	Pôle départemental du Centre de Ressources Autisme pour adultes (67) - Etablissement public de santé Alsace-Nord (site de Brumath)	Brumath
France	Centre de Ressources Autisme Pôle adultes (68) - Espace Autisme 68	Colmar
France	Clinique Lautréamont	Loos
France	INSERM U666 ; Pôle de Psychiatrie - Service de Psychiatrie Adulte- HUS	Strasbourg
France	Pôle régional du Centre de Ressources Autisme pour enfants et adolescents - Unité d'évaluation des troubles du développement Hôpital de l'Elsau - Pôle de Psychiatrie - Unité d'évaluation des troubles du développement Hôpital de l'Elsau - HUS	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France,